Mirum names Rob Myers CMO; Joanne Quan exits with severance

Mirum Pharmaceuticals, Inc.

Rob Myers, M.D. appointed Chief Medical Officer, effective Sept 21, 2026, succeeding Joanne Quan, M.D.
Joanne Quan ceased as CMO Sept 2, 2026; employment termination expected Oct 19, 2026.
Separation agreement: vested stock option exercise period extended to 12 months post-separation; 2026 annual bonus paid at 100% target.
Benefits contingent on customary conditions; separation qualifies as involuntary under Severance Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.